Mice Lacking Multidrug Resistance Protein 1a Show Altered Dopaminergic Responses to Methylenedioxymethamphetamine (MDMA) in Striatum

Overview

Journal Neurotox Res

Publisher Springer

Specialty Neurology

Date 2009 Oct 24

PMID 19851718

Citations 2

Authors

Karl B Scheidweiler

Bruce Ladenheim

Jean Lud Cadet

Marilyn A Huestis

Affiliations

Soon will be listed here.

Abstract

Multidrug resistance protein 1a (MDR1a) potentiated methylenedioxymethamphetamine (MDMA)-induced decreases of dopamine (DA) and dopamine transport protein in mouse brain one week after MDMA administration. In the present study, we examined if mdr1a wild-type (mdr1a +/+) and knock-out (mdr1a -/-) mice differentially handle the acute effects of MDMA on the nigrostriatal DA system 0-24 h following a single drug injection. 3-way ANOVA revealed significant 2-way interactions of strain x time (F (5,152) = 32.4, P < 0.001) and strain x dose (F (3,152) = 25.8, P < 0.001) on 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratios in mdr1a +/+ and -/- mice. 0.3-3 h after 10 mg/kg MDMA, DOPAC/DA ratios were increased in mdr1a +/+ mice, but decreased 0.3-1 h after MDMA in mdr1a -/- mice. Twenty-four hours after 10 mg/kg MDMA, DOPAC/DA ratios were increased 600% in mdr1a +/+ mice compared to saline-treated control mice, while in mdr1a -/- mice DOPAC/DA ratios were unchanged. Striatal MDMA and its metabolite, methylenedioxyamphetamine, concentrations by gas chromatography-mass spectrometry were similar in both strains 0.3-4 h after MDMA, discounting the role of MDR1a-facilitated MDMA transport in observed inter-strain differences. Increased DOPAC/DA turnover in mdr1a +/+ mice following MDMA is consistent with the previous report that MDMA neurotoxicity is increased in mdr1a +/+ mice. Increased DA turnover via monoamine oxidase in mdr1a +/+ vs -/- mice might increase exposure to neurotoxic reactive oxygen species.

Citing Articles

Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats.

Schindler C, Thorndike E, Blough B, Tella S, Goldberg S, Baumann M Br J Pharmacol. 2013; 171(1):83-91.

PMID: 24328722 PMC: 3874698. DOI: 10.1111/bph.12423.

(±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice.

Scheidweiler K, Ladenheim B, Barnes A, Cadet J, Huestis M J Anal Toxicol. 2011; 35(7):470-80.

PMID: 21871156 PMC: 6684102. DOI: 10.1093/anatox/35.7.470.

References

Partilla J, Dempsey A, Nagpal A, Blough B, Baumann M, Rothman R . Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther. 2006; 319(1):237-46. DOI: 10.1124/jpet.106.103622. View

Kolbrich E, Goodwin R, Gorelick D, Hayes R, Stein E, Huestis M . Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit. 2008; 30(3):320-32. PMC: 2663855. DOI: 10.1097/FTD.0b013e3181684fa0. View

OShea E, Easton N, Fry J, Green A, Marsden C . Protection against 3,4-methylenedioxymethamphetamine-induced neurodegeneration produced by glutathione depletion in rats is mediated by attenuation of hyperthermia. J Neurochem. 2002; 81(4):686-95. DOI: 10.1046/j.1471-4159.2002.00844.x. View

Linnet K, Ejsing T . A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol. 2007; 18(3):157-69. DOI: 10.1016/j.euroneuro.2007.06.003. View

HALL A, Henry J . Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth. 2006; 96(6):678-85. DOI: 10.1093/bja/ael078. View

Giros B, Jaber M, Jones S, Wightman R, Caron M . Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 1996; 379(6566):606-12. DOI: 10.1038/379606a0. View

Huang N, Wan F, Tseng C, Tung C . Amphetamine induces hydroxyl radical formation in the striatum of rats. Life Sci. 1997; 61(22):2219-29. DOI: 10.1016/s0024-3205(97)00924-7. View

Karlsen S, Spigset O, Slordal L . The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine. Basic Clin Pharmacol Toxicol. 2007; 102(1):15-24. DOI: 10.1111/j.1742-7843.2007.00159.x. View

Riddle E, Fleckenstein A, Hanson G . Role of monoamine transporters in mediating psychostimulant effects. AAPS J. 2006; 7(4):E847-51. PMC: 2750953. DOI: 10.1208/aapsj070481. View

10.

Ho R, Kim R . Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005; 78(3):260-77. DOI: 10.1016/j.clpt.2005.05.011. View

11.

Zhou S . Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008; 38(7-8):802-32. DOI: 10.1080/00498250701867889. View

12.

Crowe A, Diep S . pH dependent efflux of methamphetamine derivatives and their reversal through human Caco-2 cell monolayers. Eur J Pharmacol. 2008; 592(1-3):7-12. DOI: 10.1016/j.ejphar.2008.06.090. View

13.

Erives G, Lau S, Monks T . Accumulation of neurotoxic thioether metabolites of 3,4-(+/-)-methylenedioxymethamphetamine in rat brain. J Pharmacol Exp Ther. 2007; 324(1):284-91. DOI: 10.1124/jpet.107.128785. View

14.

Leonardi E, Azmitia E . MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology. 1994; 10(4):231-8. DOI: 10.1038/npp.1994.26. View

15.

Gudelsky G, Yamamoto B . Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav. 2007; 90(2):198-207. PMC: 2505334. DOI: 10.1016/j.pbb.2007.10.003. View

16.

Capela J, Carmo H, Remiao F, Bastos M, Meisel A, Carvalho F . Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol. 2009; 39(3):210-71. DOI: 10.1007/s12035-009-8064-1. View

17.

Heydari A, Yeo K, Lennard M, Ellis S, Tucker G, Rostami-Hodjegan A . Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos. 2004; 32(11):1213-7. DOI: 10.1124/dmd.104.001180. View

18.

Deng X, Ladenheim B, Jayanthi S, Cadet J . Methamphetamine administration causes death of dopaminergic neurons in the mouse olfactory bulb. Biol Psychiatry. 2006; 61(11):1235-43. DOI: 10.1016/j.biopsych.2006.09.010. View

19.

Bertelsen K, Greenblatt D, von Moltke L . Apparent active transport of MDMA is not mediated by P-glycoprotein: a comparison with MDCK and Caco-2 monolayers. Biopharm Drug Dispos. 2006; 27(5):219-27. DOI: 10.1002/bdd.501. View

20.

Bai F, Lau S, Monks T . Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. Chem Res Toxicol. 1999; 12(12):1150-7. DOI: 10.1021/tx990084t. View